Meet the Team

Vision 2030 Strategy Committee

Indu Navar

Experienced entrepreneur, CEO, and investor driving innovative tech development.

Indu, a seasoned entrepreneur, CEO, and investor, founded the Peter Cohen Foundation, operating as, a nonprofit fostering collaboration among ALS patients, researchers, and providers. With 20 years of experience in software companies, she led successful exits and M&A activities. As a former Managing Director at Woodside Capital Partners, Indu advised software firms on financing and M&A. She previously was CEO and founder of Serus Corporation, acquired by E2OPEN, and contributed to WebMD and Silicon Graphics. Her career began at NASA. Indu holds a B.S. in Electrical Engineering, an M.S. in Computer Science, and pursues a Ph.D. in Neuroscience.

Bill Nuti

Technology Leader and Board Director in the Fortune 500

Bill Nuti, a seasoned technology executive and board director with a distinguished career in Fortune 500 companies, merged his foundation CURE/ALS with EverythingALS to become Chairman of the combined entity, a non-profit inspired by Peter Cohen’s legacy that employs technology innovations and data science in the fight against ALS. Before this philanthropic venture, Bill led NCR Corporation as Chairman and CEO, transforming it into a software and services leader and marking his tenure with strategic achievements before retiring in 2018 due to an ALS diagnosis. With previous roles including CEO of Symbol Technologies and senior executive positions at Cisco Systems, Bill has been a dynamic force in technology, recognized for his leadership and advocacy in policy circles in Washington, D.C. His efforts have earned him recognition from Time Magazine and a Lifetime Achievement Award from the ATM Industry Association. Now focusing on EverythingALS’s mission to leverage data for ALS care and cure, Bill, a finance and economics graduate from Long Island University, resides in New York with his wife, Michele, combining his corporate acumen and advocacy to make a meaningful impact in the ALS community.

Jerry Newman

Senior Advisor driving transformative change in healthcare with extensive technology investment experience.

Jerry has over 4 decades of NASDAQ Trading, Institutional Investor coverage as well as technology and health care private and public funding. He has and continues to hold board of governor and board of trustee positions at leading hospitals, specializes in advising (predominately) health care startups with early funding and growth strategies, as well as M&A and IPO transactions. Jerry’s illustrious career includes leadership positions at top-tier investment banks such as Bear Stearns, Merrill Lynch, Cowen and JP Morgan. He holds a B.A. from San Francisco State University and an MPA from Golden Gate University.

Research Collaborators

Founding Collaborators

Dr. Merit Cudkowicz

Distinguished neurologist & ALS researcher at Mass General and Harvard Medical School

Dr. Merit Cudkowicz is the Chair of the Department of Neurology and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School in Boston. Dr. Cudkowicz is one of the founders and former co-directors of the Northeast ALS Consortium (NEALS), a group of over 150 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative academic-led clinical trials and research studies in ALS. She is leading the first Platform Trial initiative in ALS and is also the Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). Dr. Cudkowicz also mentors neurologist in careers in experimental therapeutics.

Ernest Fraenkel, PhD

Professor at Massachusetts Institute of Technology

Ernest Fraenkel is the Grover M. Hermann Professor in Health Sciences and Technology at MIT. His laboratory works at the cutting edge of computer science and biological engineering. They develop computational and experimental approaches to find new therapeutic strategies for diseases by generating and integrating molecular, clinical and behavioral data. Much of their work focuses on neurodegenerative diseases, especially ALS, including groundbreaking work using induced pluripotent stem cells from people living with ALS to map the molecular changes that distinguish different types of the disease. He has been an advisor to Everything ALS since it was founded and has helped to guide development of its research program.